Thank you, Mr. Dhaliwal.
My question is for Ms. Dey from the Council of Canadians.
My question is regarding your modelling on the effects of a two-year patent extension to the biologics, which would affect biosimilars. Have you modelled in that and worked with groups like patient advocacy groups to understand the balancing of the need for new biologics and the extensive research that goes into them, as well as patient access, and then factored in reforms at the PMPRB, potential reforms at CADTH and CDR, as well as pharmacare plans, which are obviously being discussed after Dr. Hoskins' report?